PBAC's latest decision on Eplerenone: Noted (2025). Considered for Chronic heart failure with left ventricular ejection fraction ≤40%, either within 3-14 days following acute myocardial infarction or in symptomatic patients with NYHA class II, III or IV heart failure.
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2005
Submissions
2
2005 → 2025
Eligible population
Adult patients with chronic heart failure and documented LVEF ≤40%, either within 3-14 days following acute myocardial infarction or with symptomatic NYHA class II, III or IV heart failure, receiving concomitant optimal standard chronic heart failure treatment including beta-blocker and ACE inhibitor or angiotensin II antagonist.
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
EPHESUS, EMPHASIS-HF
Comparator
standard of care / placebo
Economic model
Not modelled
ICER note
No ICER calculated; this is a Category 3 submission requesting restriction amendments to an existing listing, not a new economic evaluation.
Submission history
Jul 2005: Recommended with restriction · Authority Required